Get started
3/6/25 - $avgo - #3 semi. it's a buy.3/6/25 :: VROCKSTAR :: NASDAQ:AVGO #3 semi. it's a buy. - guys - this isn't NASDAQ:MRVL - if NASDAQ:NVDA and NYSE:TSM are S tier... i also like NASDAQ:MU as a supporting actor here (same line of thinking as NYSE:TSM ) - but at 3% fcf yields, 30x PE growing 30%+ - tough to not like this - let's see what jobz brings tmr, that could determine everything (as a multiplier here) - so while i'm on the sidelines - in any other tape i'd go long w you - "party time, excellent" - i own NASDAQ:NVDA , NYSE:TSM and NASDAQ:MU which will benefit from this and where i like my R/R better. - still cash heavy. - OTC:OBTC at 40%, NASDAQ:NXT at 30% (leveraged 2-1), NASDAQ:NVDA 5% (leveraged 2-1), NASDAQ:MU (leveraged 2-1). cash. V
NASDAQ:AVGOLong
by VROCKSTAR
$BJ bullish outlook. The 'golden cross' of moving averagesAs of March 6, 2025, BJ's Wholesale Club Holdings Inc. (NYSE: BJ) is trading at approximately $110.46 per share. Moving Averages: The 50-day moving average is currently at $100.8, while the 200-day moving average is at $91.1. This 'golden cross' indicates a bullish trend, suggesting increased short-term momentum relative to the longer-term trend. Support and Resistance Levels: Key support is around $79.28, based on recent lows. The resistance level to monitor is $99.75, aligning with previous highs. Notably, the current trading price has surpassed this resistance, potentially indicating a breakout. Relative Strength Index (RSI): The RSI is at 63.4, indicating neutral conditions; the stock is neither overbought nor oversold. Moving Average Convergence Divergence (MACD): The MACD line is above the signal line, reflecting bullish momentum and the possibility of continued price appreciation. Recent Performance: BJ's Wholesale Club recently reported strong fourth-quarter earnings, with shares rising after providing a full-year outlook that met Wall Street's expectations. The company achieved the fastest growth in comparable-club sales in two years, driven by a 12th consecutive quarter of traffic growth, increased digital sales, and record-high membership numbers. Conclusion: The technical indicators for BJ's Wholesale Club Holdings Inc. suggest a bullish outlook. The 'golden cross' of moving averages, coupled with bullish MACD signals and recent strong performance, indicates potential for continued price appreciation. Investors should monitor these technical indicators alongside fundamental factors to assess the sustainability of this trend.
NYSE:BJ
by swingstocktraders
$MRUS is approaching a critical resistance levelThe stock has experienced notable fluctuations over the past year, reaching a 52-week high of $61.61 on May 24, 2024, and a low of $37.77 on January 13, 2025. Currently, MRUS is trading above its 50-day simple moving average (SMA) of $42.11 and its 100-day SMA of $45.67, indicating a potential bullish trend. Technical indicators such as the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) are essential in assessing the stock's momentum and potential price movements. As of February 28, 2025, the RSI for MRUS is 39.15, suggesting that the stock is neither overbought nor oversold. The MACD stands at -0.67, which could indicate a bearish signal; however, it's crucial to consider this in conjunction with other indicators. Analyst sentiment remains positive, with a consensus rating of 'Buy' and a median price target of $88.00, implying substantial upside potential from current levels. In summary, MRUS is approaching a critical resistance level. A successful breakout above this threshold could signal a continuation of the upward trend, offering significant growth opportunities. Investors should monitor volume trends and other technical indicators to confirm the strength of any potential breakout.
NASDAQ:MRUS
by swingstocktraders
$ECX - The King OrdersIf you liked the analysis, consider following me and supporting the ideas. Follow me on X too! Continuation of my analysis from 02/27/2025: My entry at 2.36 on 02/27/2025. The price sideways movement since June 2024 indicates accumulation, especially at levels above 1.90. Based on this, I took my position, and today we see a price surge driven by the announcement of a partnership with Volkswagen AG. On the other hand, earnings will be released on 03/12/2025, which, given historical trends, could bring volatility and a price drop. Take profit or hold based on base volume?
NASDAQ:ECXLong
by Mordredis
$MDB to $350+ with vector database + gen AI as tailwind!- NASDAQ:MDB is investing in R&D and recently noticed that they have developed their solution for vector database www.mongodb.com - This will be a strong tailwind for the company. In generative AI, one needs to store large embedding in a low latency databases which could efficiently be looked up. By default, no-sql databases are good for these use cases. - Pinecone is one of the best in this space, NYSE:ESTC had one but now NASDAQ:MDB is catching up and looks really promising. - P/EV multiple is very reasonable for $MDB. - PT : 350+
NASDAQ:MDBLong
by bigbull037
AVGO - Can we bounce off of good earnigns?AVGO A Powerhouse Investment Opportunity Broadcom Inc. has emerged as a standout in the tech industry, demonstrating remarkable resilience and growth potential that makes it a compelling pick for investors. Here are some key highlights that underscore its appeal: Robust Financial Performance: Broadcom consistently delivers impressive revenue growth and profitability. Its solid balance sheet, high margins, and strategic capital allocation provide investors with confidence in its long-term financial health. Diverse and Innovative Product Portfolio: With strong positions in semiconductors, enterprise software, and infrastructure solutions, Broadcom benefits from multiple revenue streams. This diversification reduces risk while positioning the company to capitalize on various market trends. Strategic Acquisitions and Partnerships: Broadcom has a proven track record of making smart acquisitions and forging strategic partnerships. These moves not only expand its technological capabilities but also open up new market opportunities. Leadership in a High-Demand Industry: As the global demand for high-speed connectivity, cloud computing, and next-generation technologies continues to surge, Broadcom is well-positioned to meet these needs with its cutting-edge solutions. Investor Confidence: The company’s consistent performance, coupled with its forward-looking strategy, has earned the trust of both institutional and retail investors. Its commitment to innovation and efficiency makes it a stock to watch for long-term growth. Overall, Broadcom stands out as a reliable and dynamic investment, poised to thrive in the evolving tech landscape. For investors looking to add a resilient, high-performing asset to their portfolio, Broadcom stock is certainly a top contender. Entry: 191 Target 1 - 219 Target 2 - 244 SL Just below the gap which will serve as our insurance : 176
NASDAQ:AVGOLong
by DG55Capital
Long Thesis on BioNTech SE Post-EarningsBioNTech SE presents a compelling long opportunity following its latest earnings report. The company continues to expand beyond COVID-19 vaccines, with a strong pipeline in personalized mRNA cancer therapies, infectious disease vaccines (HIV, tuberculosis, malaria), and autoimmunity treatments. With €17 billion in cash reserves, minimal debt, and high gross margins (~77%), BioNTech remains financially resilient. Key catalysts for a bullish scenario include: ✅ Successful clinical trials in oncology with accelerated regulatory approvals. ✅ Expansion of BioNTainer production units, enabling decentralized vaccine manufacturing. ✅ New strategic partnerships in the biotech and pharma sector. ✅ Increased demand for mRNA-based flu and variant-specific COVID-19 vaccines. With analysts setting a fair value target of ~$150, the stock's current price (~$100) offers a 33% upside potential. A post-earnings rally towards 130–150 USD is plausible if BioNTech demonstrates strong progress in its oncology segment and secures additional licensing deals.
NASDAQ:BNTXLong
by rencus30
Premarket Analysis: SCNX - Scienture Holdings Breakout NewsPurchased shares of SCNX at $2.89 after the company had a breakout, releasing news of partnering with Kindeva to launch the 10mg Rezenopy nasal spray for opioid overdose treatment. We're looking for a $4.92 retest, entering with a $2.22 stop loss on the Trade. FINANCIAL NEWS: 7:41 AM EST, March 06, 2025 (Benzinga Newswire) SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024. Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY® (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY® in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure. REZENOPY® is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids. The addition of REZENOPY® to Scienture's product portfolio aligns with Scienture's mission to provide innovative treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose. As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts. Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.
NASDAQ:SCNXLong
by MyMIWallet
Pre-Market Update: OLNOLIN bounced off of the $22.98 after breaking/retesting Downward Trend Support Levels that have been support since Sept 2024. We are looking for a Top-Level Resistance breakout back to the $28 - $ 30s for a decent 20-30% in the Trade. If not, back to the 50% Retracement around the $36.26 over a longer timeframe if the company can reverse the recent stock pullbacks. Analysts have a $33 Price Target on this as well so potential for a quick breakout play here.
NYSE:OLNLong
by MyMIWallet
$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9) Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble? CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍 (2/9) – PRICE PERFORMANCE 📊 • Current Trend: Up 9% after CEO’s $5M buy on Mar 5, 2025 💰 • Context: Biotech’s a rollercoaster—posts on X show optimism 📈 • Sector Vibe: Volatile, but insider faith lifts spirits 🌈 It’s a wild climb—buckle up! ⚡ (3/9) – MARKET POSITION 📈 • Market Cap: Around $12B (based on 384M shares, est.) 🏅 • Operations: mRNA pioneer, vaccines to cancer therapies ⏳ • Trend: CEO’s move signals undervaluation hope 🎯 Solid player in the biotech jungle! 🌋 (4/9) – KEY DEVELOPMENTS 🔑 • Insider Buying: CEO’s $5M grab on Mar 5, 2025 🔄 • Buzz: Posts on X tie surge to leadership confidence 🌐 • Reaction: Market cheers, up 9% in a blink 📣 Risin’ like dough in a warm oven! 🔥 (5/9) – RISKS IN FOCUS ⚠️ • Volatility: Biotech swings wild amid macro uncertainty 🔎 • Policy: Healthcare shifts could sting 📉 • Pipeline: New products unproven, per X chatter 🌬️ High stakes, high drama! 🎭 (6/9) – SWOT: STRENGTHS 💪 • Innovation: mRNA tech reshapes medicine 🏆 • Confidence: CEO’s $5M bet screams belief 📊 • Legacy: COVID vaccine king, still swinging ⚒️ A biotech beast with bite! 🐺 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️ • Weaknesses: Volatility, macro jitters hit hard 📉 • Opportunities: New mRNA goodies, partnerships loom 📈 Can it brew more magic or fizzle out? 🧪 (8/9) – 📢 Stock up 9% after CEO’s $5M buy—your call? 🗳️ # • Bullish: $50+ soon, biotech boom 🚀 • Neutral: Holding steady, risks weigh ⚖️ • Bearish: $25 looms, bubble bursts 🐻# Drop your vote below! 👇 (9/9) – FINAL TAKEAWAY 🎯 Moderna’s 9% pop on insider buying hints at hidden gems 📈, but biotech’s a stormy sea 🌊. Dips are our playground—DCA heaven 💸. Snag ‘em cheap, ride the wave! Winner or wild card?
NASDAQ:MRNALong
by DCAChampion
6